103203-38-9

Basic information

• Product Name: 5-METHOXY-3-METHYLPHTHALIC ACID
• Synonyms: 5-METHOXY-3-METHYLPHTHALIC ACID;5-methoxy-3-methyl-1,2-Benzenedicarboxylic acid
• CAS NO: 103203-38-9
• Molecular Formula: C₁₀H₁₀O₅
• Molecular Weight: 210.18
• Mol File: 103203-38-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 399.7°Cat760mmHg
• Flash Point: 161.1°C
• Appearance: /
• Density: 1.358g/cm³
• Vapor Pressure: 4.16E-07mmHg at 25°C
• Refractive Index: 1.581
• CAS DataBase Reference: 5-METHOXY-3-METHYLPHTHALIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXY-3-METHYLPHTHALIC ACID(103203-38-9)
• EPA Substance Registry System: 5-METHOXY-3-METHYLPHTHALIC ACID(103203-38-9)

Safety Data

• Hazardous Substances Data: 103203-38-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H10O5/c1-5-3-6(15-2)4-7(9(11)12)8(5)10(13)14/h3-4H,1-2H3,(H,11,12)(H,13,14)

Upstream product

• 94742-92-4 methyl 2-bromo-5-methoxy-3-methylbenzoate 
• 94742-89-9 methyl 6-bromo-3-hydroxy-5-methylbenzoate 
• 2615-71-6 3-hydroxy-5-methyl-benzoic acid methyl ester 
• 90888-28-1 6-methoxy-4-methylisobenzofuran-1(3H)-one 
• 94742-93-5 methyl 2-cyano-5-methoxy-3-methylbenzoate 
• 4821-92-5 5-hydroxy-3-methyl-phthalic acid 
• 77-78-1 dimethyl sulfate 

Relevant articles and documents

PHARMACEUTICAL COMPOUNDS

The invention provides a compound for use in medicine, the compound being a compound of the formula (VI0) or a salt, solvate, tautomer or N-oxide thereof: wherein the bicyclic group: is selected from the structures C1, C5 and C6: wherein n is 0, 1, 2 or 3; R1 is hydrogen, hydroxy, or O—Rz; R2a is hydroxy, methoxy or O—Rz; provided that at least one of R1 and R2a is O—Rz; Rz is Lp-Rp1; SO3H; a glucuronide residue; a mono-, di- or tripeptide residue; or Lp is a bond, C═O, (C═O)O, (C═O)NRp1 or S(O)xNRp1; x is 1 or 2; Rp1 is hydrogen or a an optionally substituted C1-25 hydrocarbyl group containing 0, 1 or 2 carbocyclic rings and 0, 1, 2, 3, 4, 5 or 6 carbon-carbon multiple bonds, provided that Rp1 is not hydrogen when Lp is a bond, C═O or (C═O)O; and provided also that O—Rz does not contain an O—O moiety; and excluding compounds wherein R1 is hydroxy and R2a is methoxy; Rp2 and Rp3 are the same or different and each is a group Rp1; and R3, R4a, R8 and R10 are defined in the claims. The compounds of formula (VI0) are pro-drugs of parent compounds wherein R1 and/or R2a are hydroxy, wherein the parent compounds have Hsp90 inhibiting activity.

PHARMACEUTICAL COMBINATIONS

The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group -(O)n-R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 and/or glycogen synthase kinase-3 and/or cyclin dependent kinase inhibitors.

Phenanthrene Synthesis: The Synthesis of Effusol a 9,10-Dihydrophenanthrene from the Marsh Grass Juncus effusus

The synthesis of 5-ethenyl-1-methyl-9,10-dihydrophenanthrene-2,7-diol (effusol) (1), a natural product isolated from the marsh grass, Juncus effusus, is described.The key step was the intramolecular Ullmann reaction of methyl 2-bromo-3-2'-(6''-bromo-3''-